Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIENA: Selinexor + ICED in Relapsed/Refractory B-cell NHL with Secondary CNS Involvement
NCT06552559Phase 2Recruiting
- Sponsor
- Samsung Medical Center
- Start
- May 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in B-cell non-Hodgkin lymphoma, Central Nervous System Metastasis (CNSM), sponsored by Samsung Medical Center. Started May 2024; status: recruiting.
02
Drugs
selinexor
03
Conditions
B-cell non-Hodgkin lymphomaCentral Nervous System Metastasis (CNSM)
Beyond the preview
Go deeper on NCT06552559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06552559.